We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Lilly, Cisco, KLA, Oil-Dri Corp. of America and NVE
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 4, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lilly and Co. (LLY - Free Report) , Cisco Systems, Inc. (CSCO - Free Report) , KLA Corp. (KLAC - Free Report) , Oil-Dri Corp. of America (ODC - Free Report) and NVE Corp. (NVEC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, Cisco and KLA
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Cisco Systems, Inc. and KLA Corp., as well as two micro-cap stocks Oil-Dri Corp. of America and NVE Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+31.9% vs. +26.2%). The company's Q3 earnings and sales beat estimates. Demand for its popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company's key top-line drivers.
Lilly's other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to top-line growth. It is also making rapid pipeline progress in obesity and diabetes. Its new oral GLP-1 obesity pill, Foundayo, is expected to be a commercial game-changer. Its next-generation weight loss pill, retatrutide, if approved, could become another multibillion-dollar product.
Over the past couple of years, Lilly has announced several M&A deals aimed at diversifying beyond GLP-1 drugs and expanding its presence in immunology, oncology and neuroscience. Rising pricing pressure on some drugs and potential competition in the GLP-1 market are some top-line headwinds.
Shares of Cisco have outperformed the Zacks Computer - Networking industry over the year-to-date period (+34.3% vs. +33.7%). The company's prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk's recovery broaden the growth base.
Cisco also retains operating leverage and continues to return cash to shareholders. Offsetting these positives, a hardware-led revenue mix is expected to limit gross-margin expansion, while services recovery should remain gradual. Competition across networking and security still requires sustained product execution.
Acquisition exposure and an elevated valuation leave less room for disappointment. The breadth of durable growth drivers outweighs these execution, margin and valuation risks, supporting the Outperform recommendation.
KLA's shares have outperformed the Zacks Electronics - Miscellaneous Products industry over the year-to-date period (+26.5% vs. +12.5%). The company remains positioned to outperform as AI infrastructure spending broadens demand for process control across leading-edge logic, memory and advanced packaging. Rising chip complexity, larger die sizes and tighter defect requirements should increase inspection and metrology intensity.
A growing backlog and expanding supply capacity provide visibility into 2027, while new fabs and advanced packaging offer further growth opportunities. Services add recurring revenue as the installed base expands. Operating profitability and cash generation support shareholder returns.
KLA's differentiated portfolio and scale support long-term earnings growth. Semiconductor cyclicality, customer concentration, export restrictions and elevated component costs remain risks, but structural demand and share opportunities outweigh these concerns.
Shares of Oil-Dri Corporation of America have outperformed the Zacks Chemical - Diversified industry over the year-to-date period (+43.5% vs. +23.2%). This microcap company with a market capitalization of $1.01 billion has a diversified portfolio, spanning fluids purification, cat litter, agriculture and animal health, supports its long-term growth prospects.
Exposure to multiple filtration markets and strong customer retention provide revenue stability despite demand fluctuations. Expansion across cat litter formats, private-label offerings and distribution channels creates additional growth opportunities.
Strengthening agriculture demand and Amlan's expanding customer base further support business diversification. Healthy cash generation and financial flexibility enable continued investments, strategic acquisitions and shareholder returns. Its vertically integrated operations, substantial mineral reserves and manufacturing investments reinforce supply reliability and operational resilience.
NVE's shares have outperformed the Zacks Electronics - Semiconductors industry over the year-to-date period (+35.3% vs. +9.2%). This microcap company with a market capitalization of $370.81 million has completed manufacturing expansion, which strengthens its ability to scale production while reducing the need for significant near-term capital spending.
Growing adoption of miniaturized spintronic sensors in medical devices, industrial automation and robotics provides opportunities for long-term revenue growth. Rising distributor demand, new customer engagement and early design wins could support revenue diversification and gradually reduce reliance on large orders.
NVE's differentiated sensor technology, high isolation performance and intellectual property portfolio reinforce its competitive positioning in specialized applications. Expansion into robotics, precision motion systems and power conversion offers additional growth potential as customer programs advance toward commercialization.
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Lilly, Cisco, KLA, Oil-Dri Corp. of America and NVE
For Immediate Release
Chicago, IL – November 4, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lilly and Co. (LLY - Free Report) , Cisco Systems, Inc. (CSCO - Free Report) , KLA Corp. (KLAC - Free Report) , Oil-Dri Corp. of America (ODC - Free Report) and NVE Corp. (NVEC - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Analyst Reports for Eli Lilly, Cisco and KLA
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co., Cisco Systems, Inc. and KLA Corp., as well as two micro-cap stocks Oil-Dri Corp. of America and NVE Corp.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Today's Featured Research Reports
Eli Lilly's shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the year-to-date period (+31.9% vs. +26.2%). The company's Q3 earnings and sales beat estimates. Demand for its popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company's key top-line drivers.
Lilly's other new drugs like Kisunla, Omvoh and Jaypirca are also contributing to top-line growth. It is also making rapid pipeline progress in obesity and diabetes. Its new oral GLP-1 obesity pill, Foundayo, is expected to be a commercial game-changer. Its next-generation weight loss pill, retatrutide, if approved, could become another multibillion-dollar product.
Over the past couple of years, Lilly has announced several M&A deals aimed at diversifying beyond GLP-1 drugs and expanding its presence in immunology, oncology and neuroscience. Rising pricing pressure on some drugs and potential competition in the GLP-1 market are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
Shares of Cisco have outperformed the Zacks Computer - Networking industry over the year-to-date period (+34.3% vs. +33.7%). The company's prospects are benefiting from broad demand across networking, security and collaboration. AI infrastructure orders, integrated silicon and an end-of-support refresh opportunity support a multi-year networking cycle, while newer security products and Splunk's recovery broaden the growth base.
Cisco also retains operating leverage and continues to return cash to shareholders. Offsetting these positives, a hardware-led revenue mix is expected to limit gross-margin expansion, while services recovery should remain gradual. Competition across networking and security still requires sustained product execution.
Acquisition exposure and an elevated valuation leave less room for disappointment. The breadth of durable growth drivers outweighs these execution, margin and valuation risks, supporting the Outperform recommendation.
(You can read the full research report on Cisco here >>>)
KLA's shares have outperformed the Zacks Electronics - Miscellaneous Products industry over the year-to-date period (+26.5% vs. +12.5%). The company remains positioned to outperform as AI infrastructure spending broadens demand for process control across leading-edge logic, memory and advanced packaging. Rising chip complexity, larger die sizes and tighter defect requirements should increase inspection and metrology intensity.
A growing backlog and expanding supply capacity provide visibility into 2027, while new fabs and advanced packaging offer further growth opportunities. Services add recurring revenue as the installed base expands. Operating profitability and cash generation support shareholder returns.
KLA's differentiated portfolio and scale support long-term earnings growth. Semiconductor cyclicality, customer concentration, export restrictions and elevated component costs remain risks, but structural demand and share opportunities outweigh these concerns.
(You can read the full research report on KLA here >>>)
Shares of Oil-Dri Corporation of America have outperformed the Zacks Chemical - Diversified industry over the year-to-date period (+43.5% vs. +23.2%). This microcap company with a market capitalization of $1.01 billion has a diversified portfolio, spanning fluids purification, cat litter, agriculture and animal health, supports its long-term growth prospects.
Exposure to multiple filtration markets and strong customer retention provide revenue stability despite demand fluctuations. Expansion across cat litter formats, private-label offerings and distribution channels creates additional growth opportunities.
Strengthening agriculture demand and Amlan's expanding customer base further support business diversification. Healthy cash generation and financial flexibility enable continued investments, strategic acquisitions and shareholder returns. Its vertically integrated operations, substantial mineral reserves and manufacturing investments reinforce supply reliability and operational resilience.
(You can read the full research report on Oil-Dri Corporation of America here >>>)
NVE's shares have outperformed the Zacks Electronics - Semiconductors industry over the year-to-date period (+35.3% vs. +9.2%). This microcap company with a market capitalization of $370.81 million has completed manufacturing expansion, which strengthens its ability to scale production while reducing the need for significant near-term capital spending.
Growing adoption of miniaturized spintronic sensors in medical devices, industrial automation and robotics provides opportunities for long-term revenue growth. Rising distributor demand, new customer engagement and early design wins could support revenue diversification and gradually reduce reliance on large orders.
NVE's differentiated sensor technology, high isolation performance and intellectual property portfolio reinforce its competitive positioning in specialized applications. Expansion into robotics, precision motion systems and power conversion offers additional growth potential as customer programs advance toward commercialization.
(You can read the full research report on NVE here >>>)
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners Up
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.